US 12338269
IL-2 superagonists in combination with anti-PD-1 antibodies
granted A61KA61K2039/505A61K2039/5256
Quick answer
US patent 12338269 (IL-2 superagonists in combination with anti-PD-1 antibodies) held by Medicenna Therapeutics Inc. expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Medicenna Therapeutics Inc.
- Grant date
- Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K2039/5256, A61K2039/55533, A61K35/76